[
  {
    "ts": null,
    "headline": "This Pick Withstood the GLP-1 Challenge. Stick With the Stock.",
    "summary": "One year ago, we recommended buying  ResMed  stock after concerns that weight loss drugs would hurt demand for its sleep apnea treatments knocked shares down.  The market was concerned a new  Eli Lilly  pill would reduce patients’ obstructive sleep apnea, or OSA, enough to lower demand for ResMed’s CPAP machines and masks.  From that point—even as Lilly started selling its OSA treatment—ResMed’s earnings grew aggressively.",
    "url": "https://finnhub.io/api/news?id=f34de7c293b28fbb2adaae0364a37e9a5729bac4aeb879e72bb2188e6d87b529",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752728400,
      "headline": "This Pick Withstood the GLP-1 Challenge. Stick With the Stock.",
      "id": 135993035,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "One year ago, we recommended buying  ResMed  stock after concerns that weight loss drugs would hurt demand for its sleep apnea treatments knocked shares down.  The market was concerned a new  Eli Lilly  pill would reduce patients’ obstructive sleep apnea, or OSA, enough to lower demand for ResMed’s CPAP machines and masks.  From that point—even as Lilly started selling its OSA treatment—ResMed’s earnings grew aggressively.",
      "url": "https://finnhub.io/api/news?id=f34de7c293b28fbb2adaae0364a37e9a5729bac4aeb879e72bb2188e6d87b529"
    }
  }
]